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Abstract 1 
The aim of this study was to investigate the acute effect of hydration status on glycemic 2 
regulation in healthy adults and explore underlying mechanisms. In this randomized crossover 3 
trial, 16 healthy adults (8 male) underwent an oral glucose tolerance test (OGTT) when 4 
hypohydrated and rehydrated, after four days of pre-trial standardization. One day pre-OGTT, 5 
participants were dehydrated for 1-h in a heat-tent with subsequent fluid restriction (HYPO) 6 
or replacement (RE). The following day, an OGTT was performed with metabolic rate 7 
measures and pre- and post-OGTT muscle biopsies. Peripheral quantitative computer 8 
tomography thigh scans were taken pre- and post-intervention to infer changes in cell volume. 9 
HYPO (but not RE) induced 1.9±1.2% body mass loss, 2.9±2.7% cell volume reduction, and 10 
increased urinary hydration markers, serum osmolality, and plasma copeptin concentration 11 
(all p≤0.007). Fasted serum glucose (HYPO 5.10±0.42 mmol∙l-1; RE 5.02±0.40 mmol∙l-1; 12 
p=0.327) and insulin (HYPO 27.1±9.7 pmol∙L-1; RE 27.6±9.2 pmol∙L-1; p=0.809) 13 
concentrations were similar between HYPO and RE. Hydration status did not alter the serum 14 
glucose (p=0.627) or insulin (p=0.200) responses during the OGTT. Muscle water content 15 
was lower pre-OGTT after HYPO compared to RE (761±13 g∙kg-1 wet weight versus 772±18 16 
g∙kg-1 RE), but similar post-OGTT (HYPO 779±15 g∙kg-1 versus RE 780±20 g∙kg-1; time 17 
p=0.011; trial*time p = 0.055). Resting energy expenditure was similar between hydration 18 
states (stable between -1.21 and 5.94 kJ∙kg-1∙d-1; trial p=0.904). Overall, despite acute mild 19 
hypohydration increasing plasma copeptin concentrations and decreasing fasted cell volume 20 
and muscle water, we found no effect on glycemic regulation.  21 
 22 
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New and Noteworthy 23 
We demonstrated for the first time that an acute bout of hypohydration does not impact blood 24 
sugar control in healthy adults. Physiological responses to mild hypohydration (< 2 % body 25 
mass loss) caused an elevation in copeptin concentrations similar to that seen in those with 26 
diabetes, as well as reducing cell volume by ~3 %; both these changes had been hypothesized 27 
to cause a higher blood sugar response.  28 
 29 
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Introduction 30 
Whilst it is well-established that several dietary factors are implicated in glycemic regulation, 31 
research into the effects of hydration status is lacking. Observationally, plain water intake is 32 
typically associated with better glycemic regulation (6, 7, 26) which suggests that this could 33 
represent an inexpensive and time-efficient health intervention. However, rather than 34 
demonstrating a causal relationship, such associations may reflect water intake being a marker 35 
of a generally healthy lifestyle encompassing higher fibre intake and physical activity (19).  36 
 37 
Understanding how hydration status impacts glycemia has consequences for both clinical 38 
practice and research, whereby fasted glucose concentrations and oral glucose tolerance tests 39 
(OGTTs) are commonly used for diabetes diagnostics or to ascertain the efficacy of an 40 
intervention. Standardization of food and fluid intake prior to these measures is required to 41 
prevent confounding influences, yet hydration status is not uniformly controlled for, despite 42 
studies in adults with type 1 and 2 diabetes finding higher glycemic responses when 43 
participants were hypohydrated versus euhydrated (5, 18). One study has also shown a similar 44 
deterioration in fasting glucose in healthy adults when manipulating extracellular osmolality, 45 
which mimics some of the physiological effects of hypohydration (20). Yet, the effect of 46 
directly manipulating hydration status on glycemic control in healthy adults has, to our 47 
knowledge, never been investigated. 48 
 49 
There are several causal mechanisms through which hydration status could influence 50 
glycemia (6). Briefly, hypohydration decreases cell volume which has been hypothesized to 51 
influence glucoregulation (16, 20). Serum osmolality and arginine vasopressin (AVP) 52 
concentrations concurrently increase, potentially stimulating hepatic glucose output via 53 
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (137.222.165.060) on December 20, 2018.
5 
 
V1aR-binding in the liver (21, 29), and/or via adrenocorticotropic hormone (ACTH) and 54 
cortisol secretion. Accordingly, high plasma copeptin concentrations (a surrogate marker of 55 
AVP) concentrations (≥10.70 pmol∙L-1 in males and ≥6.47 pmol∙L-1 in females) have been 56 
associated with worse cardiometabolic health outcomes compared to those with low copeptin 57 
concentrations (≤4.59 pmol∙L-1 and ≤2.71 pmol∙L-1, respectively) (10, 11).  58 
 59 
Considering the implications for clinical practice, research, and public health, we conducted a 60 
pilot study (n=5) whereby ~12-h hypohydration (sauna plus fluid restriction) induced a higher 61 
glycemic response to an OGTT compared to sauna plus fluid replacement (8). Such findings 62 
warranted further exploration in a tightly controlled study. Therefore we aimed to investigate 63 
the role of hydration status in glycemic regulation as well as examine key mechanisms 64 
(change in cell volume and AVP secretion), hypothesizing that compared to rehydration, 65 
hypohydration would cause a higher glycemic response to an OGTT.  66 
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Methods 67 
Participants 68 
Sixteen healthy adults volunteered to participate (n = 8 males), with a mean (± standard 69 
deviation; SD) age of 30 ± 9 y, body mass of 71.7 ± 9.6 kg, and body mass index of 70 
24.0 ± 3.4 kg∙m-2. Participants were randomized using simple randomization (no strata) by 71 
HAC upon consent using a random number generator (Excel 2013, Microsoft Corp, US). 72 
Exclusion criteria were: aged < 18 y or ≥ 60 y, metabolic disease (no body mass restrictions, 73 
except self-reported weight loss > 5 kg in previous 6 mo), drug dependency, or 74 
pregnant/breastfeeding; thus all participants were considered healthy and not taking 75 
medication or necessary supplements (except contraceptives). Females not taking continuous 76 
hormonal contraceptives were tested during their estimated follicular phase (3-10 days after 77 
onset of menses). Data were collected in South West England between June 2016 and January 78 
2017, inclusive.  79 
 80 
The sample size estimate was based on our pilot project in five participants (8) showing the 81 
largest magnitude of effect at 45 minutes post-glucose ingestion (D = 1.1 mmol∙L-1). The 82 
standard deviation at this time point in the control (rehydration) group was also 1.1 mmol∙L-1, 83 
resulting in an effect size (dz) of 1. To provide a 95 % power (beta) to detect this effect at an 84 
alpha (p) of ≤ 0.05 using a two-tailed paired t-test required 16 participants. 85 
 86 
Experimental design 87 
This was a randomized crossover trial, with 5-35 d washout to account for the menstrual cycle 88 
where applicable. Each trial arm consisted of three days of between-trial physical activity and 89 
diet replication (‘pre-trial monitoring phase’), a within-participant standardized ‘intervention 90 
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day’, and a full ‘laboratory testing day’ (as detailed below and in Figure 1; trial registration 91 
can be found Clinicaltrials.gov: NCT02841449 and Open Science Framework: 92 
osf.io/ptq7msee; deviations to registered protocol are explained in full in the published 93 
dataset). The research received ethical approval from the NHS Health Research Authority 94 
Frenchay (ref: 16/SW/0057) and was conducted in accordance with the Declaration of 95 
Helsinki.  96 
 97 
Pre-trial monitoring phase  98 
Three days pre-trial, participants were asked to replicate their food/fluid intake (weighed food 99 
and fluid intake diaries; analysed using Nutritics Nutrition Analysis Software, Nutritics LTD, 100 
Dublin) and physical activity (combined heart rate and accelerometry; ActiHeart™; 101 
CamNtech, Cambridge, England), morning body mass (Inner scan; body composition 102 
monitor, model BC-543, TANITA corp. Japan) and urine specific gravity (Table 1). On the 103 
third monitoring day, participants were instructed to limit activity and to consume ≥ 40 104 
ml∙kg-1 lean body mass (assessed via bioelectrical impedance) of non-alcoholic fluid to ensure 105 
euhydration before starting the intervention. This is in line with previous research aiming to 106 
achieve euhydration (9, 22). No restrictions on caffeinated beverages were placed during this 107 
phase, though it was emphasised to participants that they would need to replicate their fluid 108 
intake in the subsequent trial arm.  109 
 110 
Diet diaries were analysed by the same coder within-participant, and the accuracy was 111 
verified by the lead author. Coding discrepancies were shared between all diet analysts to help 112 
ensure consistency between-participants. Nutrient intakes for each day of diet recording were 113 
taken from the software, and an average created for each participant. Physical activity energy 114 
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expenditure was analysed using ActiHeart 4 software which utilises a two-branch equation to 115 
estimate physical activity energy expenditure based on heart rate and accelerometry. Each 116 
ActiHeart™ was calibrated against measured resting metabolic rate for each participant and 117 
energy expenditure calculated using the ‘Group Cal JAP 2007’ model. Physical activity 118 
energy expenditure for each day was then averaged for each participant.  119 
 120 
Experimental protocol 121 
Intervention day  122 
After the pre-trial monitoring phase, participants came to the laboratory between 0600-1000 h 123 
in a euhydrated state, following overnight fluid and food abstention from 2200 h the previous 124 
day. A peripheral quantitative computer tomography (pQCT; Stratec, Pforzheim, Germany) 125 
scan of a cross-section of the midpoint of their right thigh was taken as a proxy for muscle 126 
cell volume, after which a 10 ml euhydrated baseline blood sample was taken from an 127 
antecubital vein. Blood analytes from this venepuncture further confirmed compliance to the 128 
pre-trial monitoring phase, showing that participants were in a similar metabolic state before 129 
starting each trial arm (Table 2).  130 
 131 
Participants then sat in a heat-tent (HYPO 45.2 ± 1.6°C, RE 44.6 ± 1.3°C; p = 0.292) wearing 132 
a sweat suit (RDX EVA Nylon Sauna Sweat Suit) for 60 min. Participants were nude weighed 133 
three times (Seca 803, Seca, Birmingham, UK) immediately before and after the heat-tent to 134 
determine body water losses. Post-heat-tent, participants were provided with a sandwich 135 
containing ≥ 1 g salt (Co-Operative Group Limited, UK) of their choosing (standardized 136 
within-participant; sandwiches contained 1.5 ± 0.5 g, range 1.1-2.4 g) in order to maximise 137 
fluid retention and serum osmolality changes(17), and either 3 mL∙kg-1 body mass (HYPO), 138 
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or 40 mL∙kg-1 lean body mass plus 150% sweat losses (RE) of plain water to replace losses 139 
and account for the increased drink-induced diuresis (12). All other fluids were prohibited, 140 
including those containing caffeine and alcohol. Participants were only allowed to eat from a 141 
list of low-water-content foods (e.g. pizza, biscuits, nuts; avoiding fruit, vegetables, soups and 142 
other fluids). Physical activity energy expenditure and nutrient intake profiles were similar 143 
during the intervention day (all measured nutrients p ≥ 0.102), except water intake (HYPO 144 
0.52 ± 0.11 L∙d-1 versus RE 3.7 ± 0.8 L∙d-1; p < 0.001), confirming compliance to the 145 
protocol.  146 
 147 
Laboratory testing day  148 
Participants arrived at the laboratory between 0700-0730 h after overnight food and fluid 149 
abstention from at least 2200 h the previous day, provided a urine sample and had their body 150 
mass recorded (Inner scan; body composition monitor, model BC-543, TANITA corp. Japan). 151 
A second pQCT scan of the midpoint of the right thigh was taken, after which participants 152 
were asked to rest semi-supine for 10-15 min. Their resting metabolic rate was recorded via 153 
indirect calorimetry from gaseous exchange (13), whereby 2 x 5 min measures were taken. 154 
Expired gas samples were collected in a Douglas bag (Hans Rudolph, Kansas City, USA) 155 
through falconia tubing (Baxter, Woodhouse and Taylor Ltd, Macclesfield, UK). Inspired air 156 
was simultaneously measured to adjust for ambient O2 and CO2 concentrations (4). Inspired 157 
and expired O2 and CO2 concentrations were measured using paramagnetic and infrared 158 
analysers (Mini HF 5200, Servomex Group Ltd., Sussex, UK). For metabolic rate data, n = 14 159 
as two participants were excluded from all metabolic rate and respiratory exchange ratio 160 
analyses due to fasted values > 1, which appeared to be caused by hyperventilation at these 161 
time points. In a subgroup of participants (n = 9) an additional 5 min Douglas bag was taken 162 
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at 25-30 min post-glucose ingestion to establish whether the initial diet induced 163 
thermogenesis trend was linear between 0 and 60 min. 164 
 165 
Participants then placed their hand in a hotbox (Medical Engineering Unit, University of 166 
Nottingham, UK) set to 55°C for five minutes before an indwelling cannula was fitted in an 167 
antecubital vein and a fasted blood sample was drawn. An opt-in muscle biopsy was taken 168 
(n = 9), followed by a second fasted blood sample in order to quantify any changes from the 169 
expected stress response of the biopsy. The muscle samples were acquired via a ~3 mm 170 
incision at the anterior aspect of the thigh under local anaesthetic (Lidocaine 1 %, without 171 
adrenaline; Hameln Pharmacueticals Ltd, Brockworth, UK) from the vastus lateralis by 172 
percutaneous needle biopsy technique (3). Samples were immediately removed from the 173 
needle and snap frozen in liquid nitrogen before storage at -80°C. 174 
 175 
A 75 g OGTT (Polycal, Nutricia, England) was subsequently conducted. Arterialized-venous 176 
blood samples (10 ml) were drawn at 15 min intervals for 120 min. Expired gas samples (1 x 177 
5 min Douglas bag as described previously) were collected hourly. A second muscle biopsy 178 
was then taken (for those who had opted-in; n = 7) after 120 min.   179 
 180 
Muscle water content analysis 181 
Total muscle water content was determined by weighing the biopsy samples before and after 182 
freeze drying (23). Samples were weighed on a high precision (resolution 0.01 mg) electronic 183 
balance (Mettler Toledo AE240) whilst frozen (wet weight). The time elapsed between 184 
sample removal from storage and weighing was fixed and recorded to allow for 185 
standardization of tissue water evaporation. Samples were then freeze dried using a LyoDry 186 
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Compact, MechaTech Systems freeze dryer for 24 h at -55°C before being weighed again (dry 187 
weight) using the same precision balance. Total muscle water content was calculated as grams 188 
of water per kilogram of wet muscle using the following equation: (wet weight - dry weight / 189 
wet weight) * 1000. 190 
 191 
Biochemical analysis 192 
Six millilitres of blood was decanted into two EDTA tubes and spun for 10 min at 2500-3446 193 
x g at 4°C. The remaining four millilitres of blood were decanted into a serum tube, left for at 194 
least 30 min at room temperature and then spun as per the plasma. The plasma and serum 195 
were aliquoted into separate Eppendorf tubes and frozen at ‑20°C before being moved to 196 
a -80°C freezer for longer term storage.  197 
  198 
Metabolites and hormones were measured using commercially available ELISAs (plasma 199 
arginine8 vasopressin, Enzo Life Sciences; serum insulin, Mercodia), ECLIAs (plasma 200 
ACTH, Roche), ECLIs (plasma cortisol, Roche), automated immune analyzers (plasma 201 
copeptin, ThermoFisher Kryptor Compact Plus) and spectrophotometric assays (serum 202 
glucose, RX Daytona, Randox Laboratories). Osmolality was measured using freezing-point 203 
depression (serum osmolality, Gonotec Osmomat auto; urine osmolality, Micro-Osmometer 204 
3300) and urine specific gravity was measured using a handheld refractometer (SUR-NE 205 
Clinical Refractometer, Atago, Japan). 206 
 207 
 208 
Statistical analysis 209 
The primary aim of the study was the glycemic response to an OGTT. Secondary outcomes 210 
were to investigate the insulin, vasopressin (copeptin), rested energy expenditure, and 211 
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substrate utilization responses to the OGTT, and the change in urine osmolality, urine specific 212 
gravity, cell volume, serum osmolality and muscle water content from the intervention. We 213 
were additionally able to investigate ACTH and cortisol.  214 
 215 
Data were analyzed using paired samples t-test or 2-way repeated measures (trial, time, 216 
trial*time) analysis of variance or appropriate non-parametric tests (SPSS, version 22, IBM). 217 
Normality was checked visually via P-P plots, histograms of standardized residuals, and 218 
scatterplots of the standardized predicted versus residual values. Asphericity was determined 219 
using Greenhouse-Geisser epsilon; values < 0.75 were corrected for using Greenhouse 220 
Geisser correction and values > 0.75 used Huynh-Feldt correction. Total area under the curve 221 
(AUC) and incremental AUC (iAUC) were calculated as per Wolever(30). Analyses were 222 
repeated excluding those who had muscle biopsies to explore whether their inclusion skewed 223 
the overall findings. All analyses were two-tailed with an alpha level of ≤ 0.05.  224 
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Results 225 
Markers of hydration status (body mass, urine specific gravity, urine osmolality, and cross-226 
sectional muscle area) suggested compliance to both the HYPO and RE protocol (Table 3).  227 
 228 
Serum glucose concentration 229 
Fasting serum glucose concentrations were similar between HYPO (5.10 ± 0.42 mmol∙L-1) 230 
and RE (5.02 ± 0.40 mmol∙L-1; p = 0.327). There were no differences in the glycemic 231 
response between HYPO and RE during the OGTT (trial F = 0.246, p = 0.627; time 232 
F = 41.128, p < 0.001; trial*time F = 0.944, p = 0.430; Figure 2a). No differences were found 233 
in the serum glucose iAUC (HYPO 303 ± 121 mmol*120 min∙L-1, RE 306 ± 113 mmol*120 234 
min∙L-1, p = 0.866), AUC (HYPO 926 ± 169 mmol*120 min∙L-1, RE 934 ± 120 235 
mmol*120 min∙L-1, p = 0.819), or time to peak (HYPO 46 ± 14 min, RE 48 ± 14 min, 236 
p = 0.609).  237 
 238 
Serum insulin concentration 239 
Serum insulin concentrations were similar in the fasted state (HYPO 27.09 ± 9.66 pmol∙L-1, 240 
RE 27.62 ± 9.21 pmol∙L-1; p = 0.809). During the OGTT, there were no differences between 241 
HYPO and RE in the insulinemic response (trial F = 1.800, p = 0.200; time  F= 29.597, 242 
p < 0.001; trial*time F = 0.232, p = 0.859; Figure 2b). There were no differences in the 243 
iAUC (HYPO 20860 ± 8311, RE 21937 ± 8340 pmol*120 min∙L-1, p = 0.369), AUC (HYPO 244 
23958 ± 9275 pmol*120 min∙L-1, RE 25326 ± 8679 pmol*120 min∙L-1, p = 0.359), or time to 245 
peak (HYPO 54 ± 25 min, RE 58 ± 26 min, p = 0.633) serum insulin concentrations.  246 
 247 
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Serum osmolality 248 
There was an increase from baseline in serum osmolality during HYPO of 9 ± 6 mOsm∙kg-1 249 
with relative stability from baseline during RE (Δ 1 ± 4 mOsm∙kg-1; HYPO vs RE p < 0.001; 250 
Table 3). Similar differences remained throughout the OGTT (trial F = 74.457, p < 0.001), 251 
reflected in a greater AUC during HYPO compared to RE (HYPO 35355 ± 252 
692 mOsm*120 min∙L-1, RE 34232 ± 701 mOsm*120 min∙L-1, p < 0.001).   253 
 254 
Plasma copeptin concentration 255 
Due to the difficulties in measuring AVP(24), our data were unreliable, but are available in 256 
the published dataset. Plasma copeptin was measured as a reliable marker of AVP 257 
secretion(24). Fasted (pre-biopsy) plasma copeptin concentrations increased significantly 258 
from baseline after HYPO (Δ 14.32 ± 9.32; p < 0.001) but not after RE (Δ 0.46 ± 2.34; p = 259 
0.457). Plasma copeptin concentrations were consistently higher throughout the OGTT during 260 
HYPO compared to RE (trial F = 14.193, p = 0.002; time F = 1.285, p = 0.282; trial*time F = 261 
1.396, p = 0.261; Figure 3a), confirmed by a higher AUC (HYPO 2704 ± 2398 pmol*120 262 
min∙L-1, RE 961 ± 1488 pmol*120 min∙L-1, p = 0.001).  263 
 264 
Plasma adrenocorticotropic hormone concentration (ACTH) 265 
There were no differences in the ACTH response between HYPO and RE (trial F = 2.541, 266 
p = 0.132; time F = 6.120, p = 0.025; trial*time F = 1.343, p = 0.266) during the OGTT, nor 267 
were there differences in the AUC (HYPO 405 ± 195 pmol*120 min∙L-1, RE 268 
468 ± 255 nmol*120 min∙L-1, p = 0.121).  269 
 270 
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Plasma cortisol concentration 271 
Plasma cortisol concentrations were similar between HYPO and RE (trial F= 0.216, 272 
p = 0.649; time F = 19.416, p < 0.001; trial*time F = 0.275, p = 0.674), with no differences in 273 
the plasma cortisol AUC (HYPO 35445 ± 17432 nmol*120 min∙L-1, RE 36716 ± 24915 274 
nmol*120 min∙L-1, p = 0.642).  275 
 276 
Cross-sectional muscle area 277 
Cross-sectional muscle area as a proxy for muscle cell volume reduced significantly from 278 
baseline after HYPO (Δ -2.9 ± 2.7 %; p = 0.003) but not after RE (Δ 0.0 ± 2.1 %; p = 0.936; 279 
Table 3).  280 
 281 
Muscle water content 282 
Pre-OGTT muscle biopsies showed that muscle water content was lower during HYPO 283 
(760.5 ± 13.2 g∙kg-1) compared to RE (771.6 ± 17.8 g∙kg-1) but this difference dissipated post-284 
OGTT (HYPO 778.6 ± 15.1 g∙kg-1, RE 780.2 ± 20.0 g∙kg-1; trial F = 3.183, p = 0.135; time 285 
F = 15.36, p = 0.011; trial*time F = 6.265, p = 0.055; Figure 4). 286 
 287 
Resting energy expenditure 288 
Resting metabolic rate was similar between trial arms in the fasted (HYPO 289 
96.32 ± 11.94 kJ∙d-1∙min-1, RE 95.11 ± 13.09 kJ∙kg-1∙d-1, p = 0.400) and postprandial (trial F = 290 
0.015, p = 0.904; time F = 10.130, p = 0.001; trial*time F = 0.140, p = 0.798) state. 291 
Participants had similar fasting respiratory exchange ratios (HYPO 0.84 ± 0.05, RE 292 
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0.84 ± 0.06; p = 0.900), although carbohydrate oxidation post-glucose ingestion had a 293 
tendency to increase to a greater extent in the RE trial at 60 (HYPO 0.88±0.04, RE 0.93±0.09) 294 
and 120 min (HYPO 0.87 ± 0.07, RE 0.91 ± 0.07; trial F = 3.650, p = 0.078; time F = 14.693, 295 
p < 0.001; trial*time F = 3.754, p = 0.039).   296 
 297 
Plasma volume 298 
Due to an error in postural control during the baseline (euhydrated) venepuncture, the plasma 299 
volume data were invalid. We have included details of how plasma volume was measured and 300 
the data obtained in the published dataset.  301 
 302 
Sensitivity analysis 303 
Those who had muscle biopsies demonstrated a distinct stress response in their plasma 304 
copeptin (Figure 3b), ACTH and cortisol concentrations (shown below). Removing those 305 
who had any biopsies did not alter the findings.  306 
 307 
Copeptin 308 
Removing those who had any biopsies did not meaningfully effect the trend in plasma 309 
copeptin concentration throughout the OGTT (n = 7: trial F = 13.517, p = 0.010; time 310 
F = 4.081, p = 0.040; trial*time F = 1.489, p = 0.262), though the overall AUC was lower 311 
(n = 7: HYPO 11916 ± 1661 pmol*120 min∙L-1, RE 390 ± 177 pmol*120 min∙L-1, p = 0.028).  312 
 313 
ACTH 314 
Removing those who had opted-in for muscle biopsies eliminated the time effect and 315 
highlighted a small though non-significant trend towards higher ACTH concentrations during 316 
RE compared to HYPO (n = 7: trial F = 4.203, p = 0.086; time F = 0.989, p = 0.361; 317 
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trial*time F = 1.729, p = 0.219). When biopsy participants were removed, the AUCs were 318 
lower (n = 7: HYPO 292 ± 139 pmol*120∙L-1, RE 355 ± 86 pmol*120∙L-1, p = 0.176) but 319 
there was still no difference between HYPO and RE.  320 
 321 
Cortisol 322 
In accordance with the plasma copeptin and ACTH response, plasma cortisol concentration 323 
also increased post-biopsy. Removing these participants did not meaningfully alter the results, 324 
though the time effect was no longer evident (n = 7: trial F = 0.278, p = 0.617; time 325 
F = 5.172, p = 0.055; trial*time F = 0.260, p = 0.686). Despite a post-biopsy peak in plasma 326 
cortisol concentration, the AUC was higher when the biopsy participants were removed 327 
(n = 7: HYPO 37920 ± 25008 nmol*120∙L-1, RE 40989 ± 37507 nmol*120∙L-1, p = 0.735), 328 
with no difference between HYPO and RE.  329 
 330 
Resting metabolic rate 331 
In the subgroup who had the additional measure at 30 min post-glucose ingestion (n = 9), no 332 
difference in RMR (trial F = 0.346, p = 0.573; time F = 6.087, p = 0.009; trial*time F = 333 
0.586, p = 0.508) or RER (trial F = 0.433, p = 0.529; time F = 17.330, p <0.001; trial*time 334 
F = 0.467, p = 0.607) was apparent according to hydration status. 335 
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Discussion 336 
This randomized crossover trial is the first to show that neither fasted nor postprandial 337 
glycemia or insulinemia are influenced by hydration status in healthy adults, contrary to our 338 
hypothesis. The key implication of this work is that clinicians and researchers may not have to 339 
control for hydration status when investigating glycemic regulation in healthy adults. 340 
Participants replicated their diet and activity four days pre-trial, reducing known confounding 341 
influences. Average body mass loss during HYPO was 1.9 % which is within the typical 342 
range to induce thirst and is not uncommon in the general population (2), increasing the 343 
external validity of these findings. In the hypohydrated state, copeptin (a surrogate marker of 344 
AVP) concentrations increased from levels seen in healthy adults to levels reported in those at 345 
highest risk of metabolic syndrome (10), with an accompanying reduction in muscle cell 346 
volume of ~3 %, hypothesized to be detrimental to glycemic regulation (16). Therefore the 347 
level of hypohydration achieved was sufficient to induce physiological changes that 348 
theoretically have meaningful health implications; such changes did not occur when 349 
participants were rehydrated.  350 
 351 
Despite these physiological changes hypothesized to cause higher glycemia, fasted and 352 
postprandial glycemia was similar between HYPO and RE. These results are in contrast to 353 
similar work in those with diabetes (5, 18). In both previous studies, participants were 354 
required to withdraw from diabetes medication; accordingly Burge et al. (5) found higher 355 
glucosuria when euhydrated compared to hypohydrated potentially explaining the lower 356 
glycemic response. As this effect of glucosuria has previously been alluded to (31), it is a 357 
possible (at least partial) explanation for the findings of Johnson et al. (18). This hypothesis 358 
could be tested by comparing glycemic regulation in those with diabetes during medication 359 
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withdrawal versus prescription. Glucosuria should not occur in healthy adults, potentially 360 
explaining why we did not find a lower glycemia during RE compared to HYPO.  361 
 362 
Similarly, our findings conflict with research in healthy adults. Keller et al. (20) administered 363 
intravenous saline and/or desmopressin to induce changes specifically in extra-cellular 364 
osmolality, finding higher fasted glucose concentrations during hyperosmolality. This method 365 
of dehydration however is not representative of whole body water losses, potentially 366 
explaining the discordance between our findings. The present study also contradicts our own 367 
pilot work (8), most likely because of the lack of rigorous pre-trial standardization of diet 368 
(verbal 24-h recall), physical activity (self-reported replication), and hydration status (no pre-369 
intervention measures) in the pilot.  370 
 371 
A key mechanism by which elevations in AVP induce poor glycemic control is through the 372 
hypothalamic-pituitary-adrenal (HPA) axis, stimulating ACTH and cortisol secretion. Despite 373 
the increase we observed in plasma copeptin concentrations, plasma ACTH and cortisol 374 
concentrations were not different between HYPO and RE suggesting that in healthy adults, 375 
short-term hypohydration is not a sufficient stimulus to induce a stress response along the 376 
HPA axis. This theory is in accordance with earlier work highlighting that the role of AVP in 377 
ACTH secretion is predominantly a response to physical stress (15). Nevertheless, we did not 378 
find a difference in ACTH or cortisol by hydration status in those who had the muscle 379 
biopsies, despite higher copeptin responses during HYPO. In previous work in those with 380 
type 2 diabetes, cortisol concentrations did increase 45 min post-glucose ingestion when 381 
hypohydrated (18), perhaps suggesting an interaction between hydration status and feeding in 382 
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those with metabolic impairments. However, as copeptin did not increase postprandially in 383 
our study, the mechanism for this cortisol response is unlikely to be AVP-mediated.  384 
 385 
Another mechanism proposed to link hypohydration to higher glycemia is changes to cell 386 
volume influencing insulin and glucagon secretion, though a limitation of our study is that 387 
glucagon was not measured. Muscle cell volume reduced by ~3 % from baseline, compared to 388 
no change when participants were rehydrated—a reduction that may deteriorate glucose 389 
tolerance (16, 20). The pQCT data were confirmed by the muscle biopsy samples which 390 
showed lower pre-OGTT total muscle water content in HYPO versus RE. Interestingly post-391 
OGTT the muscle water content difference diminished suggesting the introduction of glucose 392 
to the cell created a strong enough stimulus to move water from other compartments into 393 
skeletal muscle. Conversely, muscle water content did not change pre- to post-OGTT during 394 
RE, perhaps showing greater overall water balance as no extra water was needed 395 
intracellularly for glycogen storage (25).  396 
 397 
Hydration status could influence metabolic health over longer time periods by altering 398 
thermogenesis. Whilst it has been shown, albeit inconsistently, that water ingestion induces 399 
greater thermogenesis (27), our study did not support these findings, supporting evidence that 400 
the thermogenic effect is from consuming (cold) water rather than altering hydration status 401 
(27). There was a tendency for higher carbohydrate utilization during RE compared to HYPO, 402 
perhaps indicating greater hepatic glucose output during RE to account for the higher 403 
carbohydrate utilization; however these findings should be interpreted cautiously as the study 404 
was not powered for these outcomes. 405 
 406 
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There are several other speculative theories that could explain our null findings which we did 407 
not test. Firstly, it could be that healthy adults have a greater capacity to handle metabolic 408 
challenges such as acute bouts of hypohydration, and whilst physiological changes occur to 409 
handle this flux, such deviations ensure maintenance of homeostasis and therefore minimize 410 
metabolic disruption. Accordingly, both serum osmolality and plasma copeptin concentrations 411 
increased during HYPO versus RE, suggesting higher AVP secretion to help maintain 412 
homeostasis. Considering the level of HYPO we induced is not uncommon in the population 413 
(2) and caused an increase in copeptin concentrations associated with poor cardiometabolic 414 
health (10, 11), it may be that such commonly achieved levels of hypohydration have 415 
detrimental longer terms health effects not captured by our acute study design.  416 
 417 
A further hypothesis is that the conflicting roles of vasopressin receptors (VR) in adipose 418 
tissue insulin sensitivity led to a null effect on glucose tolerance during HYPO. Specifically, 419 
V1aR-/- mice have reduced adipose tissue glucose tolerance, whereas V1bR-/- mice have 420 
increased adipose tissue insulin sensitivity (1, 14, 28). If these findings translate into humans 421 
(and assuming a similar propensity for VR binding), this could mean that HYPO-induced 422 
AVP secretion, such as that achieved in our study, leads to AVP binding on both V1aR and 423 
V1bR resulting in net zero effect on glycemic regulation. However, the present study was not 424 
equipped to examine this speculative theory.  425 
 426 
Overall, despite physiologically and clinically meaningful increases in plasma copeptin and 427 
serum osmolality, and a notable reduction in cell volume supporting a systemic difference in 428 
hydration status between trial arms, we demonstrated for the first time that acute 429 
hypohydration did not alter the glycemic response. Our findings suggest that when conducting 430 
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OGTTs in healthy adults, hydration status may not necessarily need to be strictly controlled 431 
for. Although longer-term research is needed to understand the glucoregulatory effects of 432 
chronic hypohydration, these data suggest that acute manipulations of hydration status in 433 
healthy adults do not impact fasted or postprandial glycemic regulation.  434 
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Figure legends 548 
Figure 1. Protocol schematic. *muscle biopsies were taken only in those who opted in. 549 
**RMR at 30 min taken in subsample (n = 9). Abbreviations: OGTT, oral glucose tolerance 550 
test; pQCT, peripheral quantitative computer tomography scan; RMR, resting metabolic rate 551 
 552 
Figure 2. (a) Serum glucose (trial F = 0.246, p = 0.627; time F = 41.128, p < 0.001; trial*time 553 
F = 0.944, p = 0.430) and (b) insulin (trial F = 1.800, p = 0.200; time  F= 29.597, p < 0.001; 554 
trial*time F = 0.232, p = 0.859) responses to a 75 g oral glucose tolerance test (n = 16). Data 555 
are means and normalized 95% confidence intervals. Abbreviations: HYPO, hypohydrated 556 
trial arm; RE, rehydrated trial arm 557 
 558 
Figure 3. (a) Plasma copeptin response during an oral glucose tolerance test (n = 16; trial F = 559 
14.193, p = 0.002; time F = 1.285, p = 0.282; trial*time F = 1.396, p = 0.261). (b) Plasma 560 
copeptin response during an oral glucose tolerance test separating those who had muscle 561 
biopsies on both trials (n = 7) to those who had no biopsies on neither trial (n = 7). For those 562 
who had biopsies, a fasted blood sample was taken before the biopsy (time point ‘Pre-563 
biopsy’) and after the biopsy immediately before the glucose was ingested (time point ‘0’), 564 
and for those who did not have the biopsies, only one fasted sample was taken (time point 565 
‘0’). *p < 0.050, **p < 0.010 comparing HYPO and RE (trial effect) after Bonferroni 566 
adjustment for multiple comparisons. Error bars: normalized 95% confidence intervals. 567 
Abbreviations: HYPO, hypohydrated trial arm; RE, rehydrated trial arm 568 
 569 
Figure 4. Average (thick lines) and individual (thin lines) muscle water content pre-OGTT 570 
and post-OGTT during HYPO and RE (n = 6; trial F = 3.183, p = 0.135; time F = 15.36, p = 571 
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0.011; trial*time F = 6.265, p = 0.055). *p-value Bonferroni adjusted for multiple 572 
comparisons. Black lines are HYPO; grey lines are RE. Abbreviations: HYPO, hypohydrated 573 
trial arm; OGTT, oral glucose tolerance test; RE, rehydrated trial arm 574 
 575 
 576 
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Table 1: Mean ± SD of lifestyle factors and markers of hydration status during the 3-day pre-
trial monitoring phase (n = 16) 
 Hypohydration Rehydration  
 Mean ± SD Mean ± SD p-value 
1 
Energy intake (kJ∙day-1) 9777 ± 3765 10091 ± 3513 0.541 
Carbohydrate (g∙day-1) 274 ± 125 271 ± 125 0.829 
Fat (g∙day-1) 84 ± 51 93 ± 53 0.258 
Protein (g∙day-1) 105 ± 52 103 ± 41 0.729 
Sodium (mg∙day-1) 2487 ± 1774 2497 ± 1156 0.970 
Potassium (mg∙day-1) 3486 ± 3417 2778 ± 1347 0.128 
Water (L∙day-1 food + fluid) 3.3 ± 1.5 3.2 ± 1.4 0.315 
Physical activity energy expenditure (kJ∙day-1) 4462 ± 2276 4314 ± 1764 0.381 
Body mass (kg) 71.7 ± 9.6 71.8 ± 9.8 0.340 
Body mass index (kg∙m-2) 23.6 ± 4.2 23.2 ± 4.8 0.409 
USG  1.018 ± 0.005 1.018 ± 0.005 0.932 
1 
Statistical significance calculated using two-tailed paired t-test.  
Abbreviations: SD, standard deviation; USG, urine specific gravity 
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Table 2: Overnight fasted concentrations of blood hormones and metabolites in a euhydrated 
state at baseline before each trial arm (n = 16) 
 Pre-hypohydration Pre-rehydration  
 Mean ± SD Mean ± SD p-value
1 
Plasma ACTH (pmol∙L-1) 3.54 ± 1.98 3.61 ± 1.48 0.841 
Plasma copeptin (pmol∙L-1) 4.45 ± 2.01 4.25 ± 1.83 0.462 
Plasma cortisol (nmol∙L-1) 316 ± 162 330 ± 269 0.687 
Serum glucose (mmol∙L-1) 5.04 ± 0.30 4.98 ± 0.46 0.493 
Serum insulin (pmol∙L-1) 30.4 ± 11.3 29.8 ± 11.0 0.852 
Serum osmolality (mOsm∙kg-1) 287 ± 6 285 ± 4 0.152 
1 
Statistical significance calculated using two-tailed paired t-test.  
Abbreviations: ACTH, adrenocorticotropic hormone; SD, standard deviation 
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 Table 3: Mean ± SD markers of hydration status between the morning of the intervention day (euhydrated state) and full laboratory testing day  
1 Statistical significance calculated using paired t-test.  
Abbreviations: BL, euhydrated baseline measure from the morning of the intervention day; CI, confidence interval; CSMA, cross-sectional 
muscle area; HYPO, hypohydrated trial arm; FT, full trial day; RE, rehydrated trial arm; SD, standard deviation; USG, urine specific gravity 
 Hypohydration Rehydration   
 BL 
(Mean ± 
SD) 
FT 
(Mean ± 
SD) 
Δ BL to FT HYPO 
(95 % CI) 
BL 
(Mean ± 
SD) 
FT 
(Mean ± 
SD) 
Δ BL to FT RE 
(95 % CI) 
pdifference BL 
HYPO  vs 
RE1 
pdifference FT 
HYPO vs 
RE1 
Body mass (kg) 71.6 ± 9.8 70.3 ± 9.7 -1.3 (-1.8, -0.8) 71.5 ± 9.8 71.4 ± 9.9 -0.1 (-0.3, -0.1) 0.675 < 0.001 
Body water (kg) 37.3 ± 7.0 36.8 ± 6.5 -0.4 (-0.8, 0.0) 37.6 ± 5.8 37.8 ± 5.3 0.1 (-0.3, 0.6) 0.669 0.226 
CSMA (mm2) 12773 ± 
2829 
12408 ± 
2662 
-365 (-587, -138) 12682 ± 
2684 
12688 ± 
2739 
6 (-137, 148) 0.304 0.002 
USG 1.017 ± 
0.005 
1.027 ± 
0.003 
0.010 (0.007, 0.014) 1.013 ± 
0.005 
1.016 ± 
0.003 
0.003 (0.000, 0.005) 0.017 < 0.001 
Urine osmolality       
(mOsm∙kg-1) 
554 ± 185 965 ± 84 442 (355, 529) 419 ± 147 532 ± 126 93 (9, 178) 0.023 < 0.001 
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